The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.

Maio, M., Hamid, O., Larkin, J., Covre, A., Altomonte, M., Calabro, L., et al. (2020). Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. CLINICAL CANCER RESEARCH, 26(16), 4201-4205 [10.1158/1078-0432.CCR-20-1657].

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Maio M.;Covre A.;Altomonte M.;Di Giacomo A. M.
2020-01-01

Abstract

The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
2020
Maio, M., Hamid, O., Larkin, J., Covre, A., Altomonte, M., Calabro, L., et al. (2020). Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. CLINICAL CANCER RESEARCH, 26(16), 4201-4205 [10.1158/1078-0432.CCR-20-1657].
File in questo prodotto:
File Dimensione Formato  
Maio CCR-2020.pdf

non disponibili

Descrizione: Free full-text sul sito dell'editore
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 481.42 kB
Formato Adobe PDF
481.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1119775